ERBB2 and neoplasm: The quest for a potent and efficient therapy led to the development of bispecific antibodies or fragments to target more than one molecular signature (tumor associated antigens) amplified in lesions, e.g., EGFR/IGF1-R38, EGFR/Met39, and HER2/HER340.